ReviewBrain research2015
Cannabinoid modulation of drug reward and the implications of marijuana legalization.
Review in Brain research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Highway to hell or magic smoke? The dose-dependence of ΔLearning & memory (Cold Spring Harbor, N.Y.) · 2018Pooled it
- Polygenic Score × Intervention Moderation: an Application of Discrete-Time Survival Analysis to Model the Timing of First Marijuana Use Among Urban Youth.Prevention science : the official journal of the Society for Prevention Research · 2018Trial
- Adolescent ΔPharmaceuticals (Basel, Switzerland) · 2026Article
- Light Cannabis Use and the Adolescent Brain: An 8-years Longitudinal Assessment of Mental Health, Cognition, and Reward Processing.Psychopharmacology · 2024Article
- The Relationship Between Circulating Endogenous Cannabinoids and the Effects of Smoked Cannabis.Cannabis and cannabinoid research · 2023Article
- Genome-wide DNA methylation association study of recent and cumulative marijuana use in middle aged adults.Molecular psychiatry · 2023Article
- ABHD6 Controls Amphetamine-Stimulated Hyperlocomotion: Involvement of CBCannabis and cannabinoid research · 2022Article
- Abuse Potential of Synthetic Cannabinoids: AM-1248, CB-13, and PB-22.Biomolecules & therapeutics · 2021Article
- Cannabinoid type 1 receptors in A2a neurons contribute to cocaine-environment association.Psychopharmacology · 2021Article
- β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors PossiblyFrontiers in pharmacology · 2021Article
- Endocannabinoid Modulation of Nucleus Accumbens Microcircuitry and Terminal Dopamine Release.Frontiers in synaptic neuroscience · 2021Review
- Alterations in Rat Accumbens Dopamine, Endocannabinoids and GABA Content During WIN55,212-2 Treatment: The Role of Ghrelin.International journal of molecular sciences · 2020Article
- Intrinsic Frontolimbic Connectivity and Mood Symptoms in Young Adult Cannabis Users.Frontiers in public health · 2019Article
- Effects of an early life experience on rat brain cannabinoid receptors in adolescence and adulthood.IBRO reports · 2018Article
- The influence of substance misuse on clinical outcomes following burn.Burns : journal of the International Society for Burn Injuries · 2017Article
- Contrasting Regulation of Catecholamine Neurotransmission in the Behaving Brain: Pharmacological Insights from an Electrochemical Perspective.Pharmacological reviews · 2017Review
- Drug-Induced Alterations of Endocannabinoid-Mediated Plasticity in Brain Reward Regions.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2016Review
- Amphetamine elevates nucleus accumbens dopamine via an action potential-dependent mechanism that is modulated by endocannabinoids.The European journal of neuroscience · 2016Article
- Hierarchical glucocorticoid-endocannabinoid interplay regulates the activation of the nucleus accumbens by insulin.Brain research bulletin · 2016Article
- A virtue analysis of recreational marijuana use.The Linacre quarterly · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Marijuana is the most popular illegal drug worldwide. Recent trends indicate that this may soon change; not due to decreased marijuana use, but to an amendment in marijuana's illegal status. The cannabinoid type 1 (CB1) receptor mediates marijuana's psychoactive and reinforcing properties. CB1 receptors are also part of the brain endocannabinoid (eCB) system and support numerous forms of learning and memory, including the conditioned reinforcing properties of cues predicting reward or punishment. This is accomplished via eCB-dependent alterations in mesolimbic dopamine function, which plays an obligatory role in reward learning and motivation. Presynaptic CB1 receptors control midbrain dopamine neuron activity and thereby shape phasic dopamine release in target regions, particularly the nucleus accumbens (NAc). By also regulating synaptic input to the NAc, CB1 receptors modulate NAc output onto downstream neurons of the basal ganglia motor circuit, and thereby support goal-directed behaviors. Abused drugs promote short- and long-term adaptations in eCB-regulation of mesolimbic dopamine function, and thereby hijack neural systems related to the pursuit of rewards to promote drug abuse. By pharmacologically targeting the CB1 receptors, marijuana has preferential access to this neuronal system and can potently alter eCB-dependent processing of reward-related stimuli. As marijuana legalization progresses, greater access to this drug should increase the utility of marijuana as a research tool to better understand the eCB system, which has the potential to advance cannabinoid-based treatments for drug addiction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.